{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:31:44Z","timestamp":1774326704668,"version":"3.50.1"},"reference-count":23,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>A positive family history is a strong and consistently reported risk factor for gastric cancer (GC). So far, it has been demonstrated that serum pepsinogens (PGs), and gastrin 17 (G17) are useful for screening individuals at elevated risk to develop atrophic gastritis but they are suboptimal biomarkers to screen individuals for GC. The main purpose of this study was to investigate serum metabolomic profiles to find additional biomarkers that could be integrated with serum PGs and G17 to improve the diagnosis of GC and the selection of first-degree relatives (FDR) at higher risk of GC development. Serum metabolomic profiles included 188 serum metabolites, covering amino acids, biogenic amines, acylcarnitines, phosphatidylcholines, sphingomyelins and hexoses. Serum metabolomic profiles were performed with tandem mass spectrometry using the Biocrates AbsoluteIDQ p180 kit. The initial cohort (training set) consisted of n = 49 GC patients and n = 37 FDR. Differential metabolomic signatures among the two groups were investigated by univariate and multivariate partial least square differential analysis. The most significant metabolites were further selected and validated in an independent group of n = 22 GC patients and n = 17 FDR (validation set). Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic power and the optimal cut-off for each of the discriminant markers. Multivariate analysis was applied to associate the selected serum metabolites, PGs, G17 and risk factors such as age, gender and Helicobacter pylori (H. pylori) infection with the GC and FDR has been performed and an integrative risk prediction algorithm was developed. In the training set, 40 metabolites mainly belonging to phospholipids and acylcarnitines classes were differentially expressed between GC and FDR. Out of these 40 metabolites, 9 were further confirmed in the validation set. Compared with FDR, GC patients were characterized by lower levels of hydroxylated sphingomyelins (SM(OH)22:1, SM(OH)22:2, SM(OH)24:1) and phosphatidylcholines (PC ae 40:1, PC ae 42:2, PC ae 42:3) and by higher levels of acylcarnitines derivatives (C2, C16, C18:1). The specificity and sensitivity of the integrative risk prediction analysis of metabolites for GC was 73.47% and 83.78% respectively with an area under the curve of the ROC curve of 0.811 that improves to 0.90 when metabolites were integrated with the serum PGs. The predictive risk algorithm composed of the C16, SM(OH)22:1 and PG-II serum levels according to the age of individuals, could be used to stratify FDR at high risk of GC development, and then this can be addressed with diagnostic gastroscopy.<\/jats:p>","DOI":"10.3390\/ijms19030750","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T12:55:23Z","timestamp":1520427323000},"page":"750","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Use of Metabolomics as a Complementary Omic Approach to Implement Risk Criteria for First-Degree Relatives of Gastric Cancer Patients"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3619-7709","authenticated-orcid":false,"given":"Giuseppe","family":"Corona","sequence":"first","affiliation":[{"name":"Immunopathology and Cancer Biomarkers Unit, IRCCS-National Cancer Institute, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-222X","authenticated-orcid":false,"given":"Renato","family":"Cannizzaro","sequence":"additional","affiliation":[{"name":"Oncological Gastroenterology Unit, IRCCS-National Cancer Institute, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmaria","family":"Miolo","sequence":"additional","affiliation":[{"name":"Oncology B Unit, IRCCS-National Cancer Institute, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1651-6653","authenticated-orcid":false,"given":"Laura","family":"Caggiari","sequence":"additional","affiliation":[{"name":"Immunopathology and Cancer Biomarkers Unit, IRCCS-National Cancer Institute, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3794-270X","authenticated-orcid":false,"given":"Mariangela","family":"De Zorzi","sequence":"additional","affiliation":[{"name":"Immunopathology and Cancer Biomarkers Unit, IRCCS-National Cancer Institute, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-5066","authenticated-orcid":false,"given":"Ombretta","family":"Repetto","sequence":"additional","affiliation":[{"name":"Immunopathology and Cancer Biomarkers Unit, IRCCS-National Cancer Institute, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6320-3054","authenticated-orcid":false,"given":"Agostino","family":"Steffan","sequence":"additional","affiliation":[{"name":"Immunopathology and Cancer Biomarkers Unit, IRCCS-National Cancer Institute, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6100-9373","authenticated-orcid":false,"given":"Valli","family":"De Re","sequence":"additional","affiliation":[{"name":"Immunopathology and Cancer Biomarkers Unit, IRCCS-National Cancer Institute, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global Cancer Incidence and Mortality Rates and Trends\u2014An Update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol. Biomarker Prev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1056\/NEJM199110173251603","article-title":"Helicobacter pylori infection and the risk of gastric carcinoma","volume":"325","author":"Parsonnet","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s10555-014-9528-y","article-title":"E-cadherin germline mutation carriers: Clinical management and genetic implications","volume":"33","author":"Corso","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.gtc.2015.05.010","article-title":"Helicobacter pylori Eradication to Eliminate Gastric Cancer: The Japanese Strategy","volume":"44","author":"Asaka","year":"2015","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2183\/pjab.87.405","article-title":"Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels\u2014\u201cABC method\u201d","volume":"87","author":"Miki","year":"2011","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000441742","article-title":"Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels\u2014The ABC Method","volume":"93","author":"Yamaguchi","year":"2016","journal-title":"Digestion"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1002\/jcp.24003","article-title":"Pharmaco-metabolomics: An emerging \u201comics\u201d tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets","volume":"227","author":"Corona","year":"2012","journal-title":"J. Cell Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/14737159.8.5.617","article-title":"Metabolomics-based methods for early disease diagnostics","volume":"8","author":"Gowda","year":"2008","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10545-010-9061-2","article-title":"A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation","volume":"33","author":"Houten","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"22840","DOI":"10.1074\/jbc.M109.032888","article-title":"Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control","volume":"284","author":"Noland","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.freeradbiomed.2007.03.034","article-title":"Trends in oxidative aging theories","volume":"43","author":"Muller","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"394A","DOI":"10.1158\/1538-7445.AM2016-394A","article-title":"Abstract 394A: Phosphatidylcholine-34:2 and -36:4 have tumor suppressive function for gastric cancer","volume":"76","author":"Kurabe","year":"2016","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4291\/wjgp.v7.i2.235","article-title":"Visualization of sphingolipids and phospholipids in the fundic gland mucosa of human stomach using imaging mass spectrometry","volume":"7","author":"Kurabe","year":"2016","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.molcel.2010.10.005","article-title":"Membranes in balance: Mechanisms of sphingolipid homeostasis","volume":"40","author":"Breslow","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc3398","article-title":"Ceramide-orchestrated signalling in cancer cells","volume":"13","author":"Morad","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1389450033347172","article-title":"Lipids as a target for drugs modulating multidrug resistance of cancer cells","volume":"4","author":"Hendrich","year":"2003","journal-title":"Curr. Drug Targets"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.bbalip.2009.12.004","article-title":"Fatty acid 2-Hydroxylation in mammalian sphingolipid biology","volume":"1801","author":"Hama","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jbior.2013.09.012","article-title":"2\u2032-Hydroxy ceramide in membrane homeostasis and cell signaling","volume":"54","author":"Kota","year":"2014","journal-title":"Adv. Biol. Regul."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.trecan.2016.12.008","article-title":"Neuronal Activity in Ontogeny and Oncology","volume":"3","author":"Venkatesh","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccell.2016.11.005","article-title":"Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling","volume":"31","author":"Hayakawa","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1038\/ctg.2016.42","article-title":"Pepsinogens to Distinguish Patients With Gastric Intestinal Metaplasia and Helicobacter pylori Infection Among Populations at Risk for Gastric Cancer","volume":"7","author":"Orzes","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"14.10.1","DOI":"10.1002\/cpbi.11","article-title":"Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis","volume":"55","author":"Xia","year":"2016","journal-title":"Curr. Protoc. Bioinform."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/3\/750\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:57:48Z","timestamp":1760194668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/3\/750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["ijms19030750"],"URL":"https:\/\/doi.org\/10.3390\/ijms19030750","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]}}}